Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.
- Advarra approves the trial protocol, consent forms and study materials
- FDA IND clearance and central IRB approval are now in place
- Site contracts, investigator training and recruitment planning are underway
- Patient enrolment will begin after the first site is activated
- The milestone provides no efficacy, safety or financial results
Central IRB Approval Clears Trial Entry Requirement
Imagion Biosystems (ASX:IBX) has removed a key ethics hurdle from its US Phase 1b/2 trial of the MagSense HER2 Imaging Agent, with Advarra granting central Institutional Review Board approval for the study. The decision covers the protocol, informed consent process and study materials, allowing the company and its clinical partners to move towards activating participating sites.
The approval comes after the US Food and Drug Administration cleared the trial’s Investigational New Drug application. Together, the two approvals provide the regulatory and ethics clearances required before patients can enter the study, although they do not amount to evidence that MagSense is effective or safe in the trial population.
Site Activation Comes Before Patient Recruitment
Imagion and its trial partners are now working through site contract execution, investigator training and recruitment planning. The company said enrolment will start only after the first site is activated, leaving the immediate operational milestone as site readiness rather than clinical readout.
Using a central IRB may reduce duplicated ethics reviews across participating locations where local rules permit reliance on the central approval. That could support a more coordinated start-up, but the announcement does not disclose the number of sites, the planned enrolment target or a timetable for first-patient dosing.
MagSense Moves Towards Phase 2 Data
MagSense uses targeted magnetic nanoparticles with MRI to seek molecularly specific cancer detection without radioactive tracers or ionising radiation. Imagion says its lead programme has already completed a Phase 1 study focused on detecting nodal metastases in HER2-positive breast cancer and is now advancing into the planned Phase 1b/2 study.
The next meaningful evidence will therefore come from execution: first-site activation, first patient enrolment and the eventual safety, dosing and diagnostic performance data. Until those milestones arrive, the ethics approval is a development advance rather than a clinical validation event.
Bottom Line?
Imagion has cleared the approval stage, but the investment case now turns on how quickly sites open and whether the trial produces credible safety and diagnostic data.
Questions in the middle?
- When will the first US site be activated and the first patient enrolled?
- How many sites and participants will form the Phase 1b/2 dataset?
- Will the trial demonstrate diagnostic performance strong enough to support later-stage development?